Business Context and Reporting Period
Company: Natural Alternatives International, Inc. (NAI)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2009 (Nine months ended March 31, 2009)
Business Overview: NAI operates two primary segments: private label contract manufacturing (providing services to companies marketing nutritional supplements) and branded products (marketing its own supplements). The company is a smaller reporting company incorporated in Delaware.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Mar 31, 2009 | Nine Months Ended Mar 31, 2009 |
|---|---|---|
| Net Sales | $17,348 | $54,490 |
| Gross Profit | $3,107 | $6,279 |
| Gross Margin % | 17.9% | 11.5% |
| Operating Income (Loss) - Continuing Ops | $1,383 | $(901) |
| Net Loss | $(504) | $(5,205) |
| Cash and Cash Equivalents | $2,712 | $2,712 (Ending Balance) |
| Total Debt (Current + Long-term) | $3,446 | $3,446 (Reclassified as Current) |
| Working Capital | $12,019 | $12,019 |
Note: All long-term debt has been reclassified as current due to covenant violations and waiver conditions (see Risks section).
Material Changes vs. Prior Period
- Revenue Decline: Net sales from continuing operations decreased 8% for the quarter and 9% for the nine-month period compared to the prior year. Private label contract manufacturing sales dropped 7% (quarter) and 8% (nine months), while branded product sales fell 35% (quarter) and 33% (nine months).
- Profitability Shift: Operating income from continuing operations improved significantly in the quarter to $1.38 million from a loss of $0.36 million in the prior year quarter, driven by cost reduction programs. However, the nine-month period showed an operating loss of $0.9 million compared to income of $0.79 million in the prior year.
- Discontinued Operations: The company recorded a significant loss from discontinued operations of $1.94 million for the quarter and $3.75 million for the nine months. This includes a $1.8 million impairment charge related to the legacy Real Health Laboratories (RHL) business and restructuring costs.
- Cash Flow: Net cash provided by operating activities was $0.78 million for the nine months ended March 31, 2009, a decrease from $2.33 million in the prior year period. Capital expenditures increased to $3.87 million (nine months) from $1.28 million, primarily for manufacturing equipment.
Guidance, Outlook, and Risks
- Outlook: Management expects reduced net sales in the fourth quarter of fiscal 2009 due to uncertain economic conditions and unfavorable currency markets. They anticipate higher per-unit operating costs due to reduced manufacturing throughput, though this is expected to be offset by the cost reduction program implemented in the second quarter.
- Cost Reduction: A program initiated in the second quarter resulted in a $0.56 million charge and is expected to reduce annual operating overhead by approximately $3.6 million.
- Debt Covenants and Liquidity Risk: The company was not in compliance with its quarterly net income and fixed charge coverage ratio covenants as of March 31, 2009. While the lender granted a waiver for a fee, the company does not expect to meet covenants as of June 30, 2009. Consequently, all long-term debt has been reclassified as current. A loan modification is required by May 22, 2009, which may reduce the available borrowing base.
- Customer Concentration: Revenue remains highly concentrated. The two largest customers accounted for 83% of net sales in the quarter and 79% for the nine-month period.
- Discontinued Operations: The company is actively marketing the legacy RHL business for sale, excluding the "Pathway to Healing" product line. Sales of this line have softened following the discontinuance of Dr. Cherry's television program.
Investor Verification Checklist
- Debt Covenant Status: Verify the terms of the required loan modification by May 22, 2009, and the likelihood of obtaining future waivers if covenants are missed in the next quarter.
- Discontinued Operations Sale: Monitor progress on the sale of the legacy RHL business and the impact of the $1.8 million impairment charge on future asset valuations.
- Customer Concentration: Assess the risk associated with the top two customers representing nearly 80% of revenue, particularly given the economic downturn affecting their order volumes.
- Capital Expenditures: Review the necessity and ROI of the $3.9 million in capital expenditures during a period of declining sales and negative operating cash flow.
- Foreign Currency Impact: Evaluate the exposure to foreign exchange losses, which contributed to a $0.43 million loss in other expenses for the nine-month period.